
Harnessing digital technologies could unlock £22 billion ($30.1 billion) for UK pharma companies over the next decade, according to Accenture.
The study found that pharma could accelerate growth by 5%, generating an estimated £12 billion in new revenue. On top of this, it could reduce costs by more than £11 billion and pass on cost savings of 10% direct to consumers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze